-
Mashup Score: 2
Although multiple myeloma remains incurable, treatment advances during the past several years have dramatically improved clinicians’ ability to slow progression of the disease.Most recently, novel T-cell-directed immunotherapies, such as chimeric antigen receptor T cells and bispecific antibodies, have extended survival and improved quality of life for many patients.
Source: www.healio.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Although multiple myeloma remains incurable, treatment advances during the past several years have dramatically improved clinicians’ ability to slow progression of the disease.Most recently, novel T-cell-directed immunotherapies, such as chimeric antigen receptor T cells and bispecific antibodies, have extended survival and improved quality of life for many patients.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Multiple myeloma cure? Immunotherapies offer incredible hope. https://t.co/KU6r7xuPL4 #CellTherapyNext #HemOnc #OncAlert #MedEd @uamshealth @uamscancer #MultipleMyeloma #Cure
-
-
Mashup Score: 0
A novel chimeric antigen receptor T-cell therapy induced clinically impactful antitumor responses in 63% of younger patients with relapsed or refractory, high-risk neuroblastoma, results of a phase 1/phase 2 trial showed.The findings, published in The New England Journal of Medicine, suggest the investigational agent also has a manageable safety profile similar to other CAR T-cell therapies,
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Breakthrough Study shows ‘CAR T CELLS CAN ERADICATE SOLID TUMORS in advanced neuroblastoma. https://t.co/5NuYCbYJz0 #CellTherapyNext #HemOnc #OncAlert #MedEd @Unicatt @Stanford #neuroblastoma
-
-
Mashup Score: 0CAR T cells improve quality of life for majority of recipients - 1 year(s) ago
Patients with hematologic malignancies reported significant improvement in quality of life after receiving chimeric antigen receptor T cells, results from a longitudinal study in Blood Advances showed. After an initial worsening of quality-of-life (QOL) measures and reported depression in the week following CAR-T infusion, researchers observed overall improvements in QOL, psychological distress
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CAR-T cells improve quality of life for majority of recipients. https://t.co/yOLNvpF2fB #CellTherapyNext @MassGeneralNews #qualityoflife #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0Lack of awareness, limited sites hinder CAR-T trials for younger patients with cancer - 2 year(s) ago
The FDA’s approval of tisagenlecleucel in 2017 resulted in an explosion of research into chimeric antigen receptor T-cell therapies.However, much of this research has focused on adults.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Less than half of U.S states have at least one center offering a pediatric CAR-T clinical trial Read the latest Pediatric Focus from #CellTherapyNext here: https://t.co/A9JFjQYLtV #onctwitter @UCSF @UCSFBenioffOAK @drkevinjcurran @MSKCancerCenter #MSKKids @StBaldricks
-
Less than half of U.S states have at least one center offering a pediatric CAR-T clinical trial Read the latest Pediatric Focus from #CellTherapyNext here: https://t.co/lR6UmYY5ev #onctwitter @UCSF @UCSFBenioffOAK @drkevinjcurran @MSKCancerCenter #MSKKids @StBaldricks
-
-
Mashup Score: 0
B-cell acute lymphoblastic leukemia is the most common type of cancer among children.It also is a contemporary treatment success story, with American Cancer Society data showing a 5-year survival rate of 90%.
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Our LATEST Pediatric Focus feature from #CellTherapyNext looks at the use #CARTcell therapy that does not meet FDA specifications in younger patients with B-cell acute lymphoblastic #leukemia https://t.co/8b5Gd9uaxZ @NUFeinbergMed @LurieChildrens @StJude @NCCN
-
-
Mashup Score: 0
B-cell acute lymphoblastic leukemia is the most common type of cancer among children.It also is a contemporary treatment success story, with American Cancer Society data showing a 5-year survival rate of 90%.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Our LATEST Pediatric Focus feature from #CellTherapyNext looks at the use #CARTcell therapy that does not meet FDA specifications in younger patients with B-cell acute lymphoblastic #leukemia https://t.co/dKTshjLpYK @NUFeinbergMed @LurieChildrens @StJude @NCCN
-
-
Mashup Score: 0Prior therapy may reduce efficacy of tumor-infiltrating lymphocytes for advanced melanoma - 2 year(s) ago
Prior treatment with newer-generation therapies appeared associated with significantly lower objective response rates among patients who received tumor-infiltrating lymphocytes for metastatic melanoma, according to study findings.Early clinical trials of adoptive tumor-infiltrating lymphocytes (TILs) for metastatic melanoma showed consistent objective response rates of approximately 50%,
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
🎙Stephanie L Goff, MD, FACS discusses research from @NIH & @theNCI showing how prior use of newer-gen therapies may reduce efficacy of tumor-infiltrating lymphocytes for advanced #melanoma https://t.co/kVdBLqj628 #TILs #CellTherapyNext @slgoff_SB
-
-
Mashup Score: 0Prior therapy may reduce efficacy of tumor-infiltrating lymphocytes for advanced melanoma - 2 year(s) ago
Prior treatment with newer-generation therapies appeared associated with significantly lower objective response rates among patients who received tumor-infiltrating lymphocytes for metastatic melanoma, according to study findings.Early clinical trials of adoptive tumor-infiltrating lymphocytes (TILs) for metastatic melanoma showed consistent objective response rates of approximately 50%,
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎙Stephanie L Goff, MD, FACS discusses research from @NIH & @theNCI showing how prior use of newer-gen therapies may reduce efficacy of tumor-infiltrating lymphocytes for advanced #melanoma https://t.co/n94FsLrQln #TILs #CellTherapyNext @slgoff_SB
-
-
Mashup Score: 0FDA grants orphan drug designation to multitargeted T-cell therapy for pancreatic cancer - 2 year(s) ago
The FDA granted orphan drug designation to MT-601, an investigational T-cell immunotherapy, for treatment of advanced or metastatic pancreatic adenocarcinoma.MT-601 (Marker Therapeutics) is an autologous, nongene-edited T-cell therapy composed of cytotoxic T lymphocyte lines that target PRAME, SSX2, MAGEA4, NY-ESO-1 and Survivin proteins on the surface of cancer cells.
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
MT-601, a multitarget T-cell therapy from @MRKRTherapeutic for pancreatic cancer, given orphan drug designation by FDA https://t.co/NE1bi5s3sG #oncology #CellTherapyNext
-
RT @HemOncToday: Multiple myeloma cure? Immunotherapies offer incredible hope. https://t.co/KU6r7xuPL4 #CellTherapyNext #HemOnc #OncAlert…